PT - JOURNAL ARTICLE AU - O. Senn AU - E. W. Russi AU - M. Imboden AU - N. M. Probst-Hensch TI - α<sub>1</sub>-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants AID - 10.1183/09031936.05.00021605 DP - 2005 Nov 01 TA - European Respiratory Journal PG - 909--917 VI - 26 IP - 5 4099 - http://erj.ersjournals.com/content/26/5/909.short 4100 - http://erj.ersjournals.com/content/26/5/909.full SO - Eur Respir J2005 Nov 01; 26 AB - Chronic obstructive pulmonary disease (COPD) is a prevalent and preventable disease associated with high morbidity and mortality. Severe and intermediate α1-antitrypsin (AAT) deficiency (serum levels &lt;11 and 11–20 µmol·L−1, respectively) increase the risk of COPD in active smokers. However, little is known about the interaction of severe and intermediate AAT deficiency with modifiable COPD risk factors other than active smoking. In this study, a MEDLINE search was carried out for studies investigating the combined effect of environmental inhalants (occupation and passive smoking) and AAT deficiency in the lung. A total of 18 studies using established methods for the assessment of AAT deficiency were included in this review. Occupational exposures and passive smoking affected lung function decline or prevalence of respiratory symptoms in four out of five studies investigating subjects with severe AAT deficiency, and in eight out of 13 studies with a focus on intermediate AAT deficiency. While study designs mostly prohibited formal assessment of effect modification, an interaction between intermediate AAT deficiency and passive smoking was identified in two studies with children. Additional study limitations included small sample size, poor adjustment for confounding and misclassification of environmental exposure as well as AAT activity. In conclusion, population-based epidemiological studies with associated biobanks are needed to identify gene–environment interactions and population subgroups susceptible to α1-antitrypsin deficiency.